Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyCentene Duobrii coverage update Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentCentenePolicy CP PMN.208

    Duobrii (halobetasol propionate / tazarotene) topical lotion — coverage criteria

    Customize your policy alerts

    Sign up for Centene Policy CP PMN.208 alerts

    Get alerted when Policy CP PMN.208 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing medical necessity and prior authorization requirements for Duobrii (halobetasol propionate 0.01%/tazarotene 0.045%) topical lotion for treatment of plaque psoriasis in adults across Centene lines of business.

    Policy Summary
    PayerCentene
    PolicyDuobrii (halobetasol propionate / tazarotene) topical lotion — coverage criteria
    Policy CodePolicy CP PMN.208
    Change TypeStep therapy modification (IL HIM bypass)
    Effective Date09.01.19
    Next Review DateN/A
    Key ActionSubmit prior authorization with supporting clinical documentation demonstrating criteria are met; approvals are for 12 months when criteria are satisfied.
    SourceLink
    POLICY UPDATE CHANGES

    Step therapy bypass for Illinois HIM per IL HB 5395 added for certain requirements.

    100 gmax monthly qty

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=18
    min age
    >=20%BSA requirement
    12 moapproval duration
    Pregnancycontraindication

    Coverage Criteria

    Initial Therapy — Covered when ALL of the following are met for Initial Approval:

    Covered when ALL of the following are met for Initial Approval:

    Initial Approval for Plaque Psoriasis: 1) Diagnosis of plaque psoriasis with body surface area involvement >= 20%; 2) Age >= 18 years; 3) Prescribed by or in consultation with a dermatologist or rheumatologist; 4) Failure of generic halobetasol propionate and generic clobetasol propionate unless both are contraindicated or there are clinically significant adverse effects (note: for Illinois HIM requests, these step therapy requirements do not apply as of 1/1/2026 per IL HB 5395); 5) Failure of generic tazarotene unless contraindicated or there are clinically significant adverse effects (note: for Illinois HIM requests, this step therapy requirement does not apply as of 1/1/2026 per IL HB 5395); 6) Dose does not exceed 100 g per month (one tube per month).

    Approval duration: 12 months

    Continuation Therapy — Covered when ALL of the following are met for Continued Therapy:

    Covered when ALL of the following are met for Continued Therapy:

    Continued Therapy for Plaque Psoriasis: 1) Member is currently receiving medication via Centene benefit or has previously met initial approval criteria (continuity of care provisions may apply per state addendums); 2) Member is responding positively to therapy; 3) If request is for a dose increase, new dose does not exceed 100 g per month (one tube per month).

    Approval duration: 12 months

    This policy applies only to the FDA‑approved indication(s) described elsewhere in the document. Non‑FDA approved indications that are not addressed in this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 (commercial), HIM.PA.154 (health insurance marketplace), or CP PMN.53 (Medicaid).

    Requests for treatment of non‑FDA approved indications that lack adequate supporting evidence per the off‑label use policies referenced in this policy will be considered not medically necessary and are not authorized. Providers should include documentation demonstrating efficacy and safety consistent with CP.CPA.09, HIM.PA.154, or CP PMN.53 when requesting coverage for off‑label use.

    Coding and Product Availability

    Product availability / packagingmixed
    NDC not listedLotion 0.019/0.045%: 100 g tubes
    Maximum monthly quantity
    Maximum monthly quantity100 g per month (one tube per month)
    Related weekly maximum50 g per week (per prescribing information)
    Approval duration when criteria met12 months
    Policy dosing weekly maximum
    Policy weekly maximum (per prescribing info)50 g per week
    Typical dosing frequencyApply a thin layer once daily to affected areas until control is achieved
    Related maximum monthly limit enforced by policy

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initial and continuation requests. Approvals (initial and continuation) are for 12 months when all criteria are met.

    • Approval duration: 12 months
    Step Therapy

    Step Therapy Requirements and IL HIM Bypass

    Step therapy is required for initial approval unless contraindicated or adverse effects occur. For Illinois Health Insurance Marketplace (HIM) requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.

    • Initial therapy requires failure of generic halobetasol propionate and generic clobetasol propionate unless both are contraindicated or cause clinically significant adverse effects.
    • Initial therapy requires failure of generic tazarotene unless contraindicated or causes clinically significant adverse effects.
    • IL HIM bypass: Step therapy requirements do not apply for Illinois HIM requests effective 01/01/2026 (IL HB 5395).

    Definitions

    Duobrii — active ingredients
    Product nameDuobrii
    Active ingredientshalobetasol propionate 0.01% / tazarotene 0.045%
    Therapeutic classesHalobetasol propionate (corticosteroid); tazarotene (retinoid)
    Dosing / Availability
    Indication and dosingPlaque psoriasis: apply a thin layer once daily to affected areas until control is achieved
    Product tube size100 g per tube
    Dose limitsMaximum 50 g/week (prescribing info); policy limits to 100 g/month (one tube/month)

    Background

    Duobrii is a fixed‑combination topical lotion containing halobetasol propionate and tazarotene (halobetasol propionate 0.01% / tazarotene 0.045%). It is indicated by the FDA for the topical treatment of plaque psoriasis in adults. The recommended administration is to apply a thin layer once daily to affected areas until control is achieved; the commercial product is supplied as a 100 g tube. Policy dosing limits include a maximum of 50 g per week per the prescribing information and a policy limit of 100 g per month (one 100 g tube) for coverage determinations.

    Policy Summary
    PayerCentene
    PolicyDuobrii (halobetasol propionate / tazarotene) topical lotion — coverage criteria
    Policy CodePolicy CP PMN.208
    Change TypeStep therapy modification (IL HIM bypass)
    Effective Date09.01.19
    Next Review DateN/A
    Key ActionSubmit prior authorization with supporting clinical documentation demonstrating criteria are met; approvals are for 12 months when criteria are satisfied.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Product AvailabilityProvider Actions and RequirementsDefinitionsBackground
    100 g per month (one tube per month)
    Documentation Required

    Required Clinical Documentation; Documentation & Indication

    Provider must submit supporting clinical documentation with the prior authorization request. Requests that lack sufficient documentation or that seek non‑FDA (off‑label) uses without adequate supporting evidence may be denied.

    • Required documentation: office chart notes, relevant laboratory results, prior medication history showing trials and failures (including dates and reasons for discontinuation), and consultation notes if applicable.
    • Documentation & Indication: If the request is for a non‑FDA approved indication, include sufficient documentation of efficacy and safety consistent with the applicable off‑label use policy (CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, CP PMN.53 for Medicaid) or evidence of coverage documents.
    • Requests lacking documentation that the member met all approval criteria or that do not justify off‑label use per the referenced policies may be denied.